Research ArticleRheumatoid Arthritis
Open Access
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi and William Macias
The Journal of Rheumatology August 2019, 46 (8) 887-895; DOI: https://doi.org/10.3899/jrheum.171469
Charles Peterfy
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware,
USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford,
UK; Department of Rheumatology, University of Toronto, Toronto, Ontario,
Canada.
Julie DiCarlo
Paul Emery
Mark C. Genovese
Edward C. Keystone
Peter C. Taylor
Doug E. Schlichting
Scott D. Beattie
Monica Luchi
REFERENCES
- 1.↵
- European Medicines Agency
- 2.↵
- 3.↵
- Smolen JS,
- Van Der Heijde DM,
- St. Clair EW,
- Emery P,
- Bathon JM,
- Keystone E,
- et al;
- Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group
- 4.↵
- Baker JF,
- Ostergaard M,
- Emery P,
- Hsia EC,
- Lu J,
- Baker DG,
- et al.
- 5.↵
- Peterfy C,
- Østergaard M,
- Conaghan PG
- 6.↵
- American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging Group and Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working Group
- 7.↵
- Conaghan PG,
- Durez P,
- Alten RE,
- Burmester GR,
- Tak PP,
- Klareskog L,
- et al.
- 8.↵
- Conaghan PG,
- Peterfy C,
- Olech E,
- Kaine J,
- Ridley D,
- Dicarlo J,
- et al.
- 9.↵
- Keystone EC,
- Taylor PC,
- Drescher E,
- Schlichting DE,
- Beattie SD,
- Berclaz PY,
- et al.
- 10.↵
- Dougados M,
- van der Heijde D,
- Chen YC,
- Greenwald M,
- Drescher E,
- Liu J,
- et al.
- 11.↵
- Taylor PC,
- Keystone EC,
- van der Heijde D,
- Weinblatt ME,
- Del Carmen Morales L,
- Reyes Gonzaga J,
- et al.
- 12.↵
- Fleischmann R,
- Schiff M,
- van der Heijde D,
- Ramos-Remus C,
- Spindler A,
- Stanislav M,
- et al.
- 13.↵
- Østergaard M,
- Peterfy C,
- Conaghan P,
- McQueen F,
- Bird P,
- Ejbjerg B,
- et al.
- 14.↵
- 15.↵
- 16.↵
- Peterfy C,
- Emery P,
- Tak PP,
- Østergaard M,
- DiCarlo J,
- Otsa K,
- et al.
- 17.↵
- Bruynesteyn K,
- Boers M,
- Kostense P,
- van der Linden S,
- van der Heijde D
- 18.↵
- 19.↵
- Rahman MU,
- Buchanan J,
- Doyle MK,
- Hsia EC,
- Gathany T,
- Parasuraman S,
- et al.
- 20.↵
- 21.↵
- U.S. Department of Health and Human Services, Food and Drug Administration
- 22.↵
- Glinatsi D,
- Lillegraven S,
- Haavardsholm EA,
- Eshed I,
- Conaghan PG,
- Peterfy C,
- et al.
- 23.↵
- Beals C,
- Baumgartner R,
- Peterfy C,
- Balanescu A,
- Mirea G,
- Harabaglu A,
- et al.
In this issue
The Journal of Rheumatology
Vol. 46, Issue 8
1 Aug 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi, William Macias
The Journal of Rheumatology Aug 2019, 46 (8) 887-895; DOI: 10.3899/jrheum.171469
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi, William Macias
The Journal of Rheumatology Aug 2019, 46 (8) 887-895; DOI: 10.3899/jrheum.171469